Artificial intelligence is rapidly transforming how one of medicine’s most information-rich cancer scans is read, and a new comprehensive review argues that lymphoma may be the field where the change hits hardest. Published in Holistic Integrative Oncology, the review systematically synthesized 53 original studies, selected from an initial pool of more than 1,000 papers under PRISMA guidelines, to map how machine learning and deep learning are reshaping every stage of fluorodeoxyglucose positron emission tomography/computed tomography, better known as FDG PET/CT, in lymphoma care. The analysis converges on three clinical battlegrounds: automated lesion segmentation, non-invasive differential diagnosis, and individualized prognostic stratification, and it suggests that the technology is now approaching a genuine inflection point between laboratory promise and bedside reality.
The case for automation begins with a measurement problem. Lymphoma is a highly heterogeneous blood cancer that can seed lesions virtually anywhere in the body, and the standard treatment of visual reading of whole-body PET scans is slow and notoriously variable between observers. One of the most powerful prognostic markers in the field, total metabolic tumor volume, or TMTV, requires clinicians to trace the boundaries of every FDG-avid lesion across an entire scan. Manual delineation is so labor-intensive and subjective that it has historically blocked the routine clinical adoption of this biomarker, despite extensive validation across diffuse large B-cell lymphoma, Hodgkin lymphoma, peripheral T-cell lymphoma, and even patients heading into CAR-T cell therapy. Traditional computer-assisted methods such as thresholding, region growing, and edge detection helped but never fully solved the reproducibility problem.
Deep learning has changed that equation. Convolutional neural networks, particularly architectures built on the three-dimensional U-Net template, can now learn directly from images how to outline tumor tissue without hand-crafted rules. The review highlights a wave of refinements tailored to lymphoma’s specific challenges. Dense U-Net variants with Tversky loss functions sharpen performance on very small lesions, which are commonly missed by generic models. Prior-shift regularization networks tackle the extreme class imbalance of whole-body scans, where tumor occupies a tiny fraction of the pixels. A longitudinally aware segmentation network tracks lesions across serial scans in pediatric Hodgkin lymphoma, improving interim treatment monitoring without sacrificing baseline accuracy. Boundary-optimized and cruciform-guided designs have pushed Dice similarity coefficients as high as 90.7 percent in some studies, while hybrid PET/CT feature fusion modules have achieved detection accuracies exceeding 99 percent in body-region-level detection tasks.
Crucially, the field is proving that these tools generalize. TMTV-Net, a cascaded 3D U-Net system, achieved comparable performance on internal test data and on independent multi-site external data, with average Dice scores around 0.66 to 0.68, a critical benchmark for regulatory and clinical credibility. Studies in diffuse large B-cell lymphoma demonstrated that fully automatic TMTV calculation from U-Net segmentations serves as an independent survival predictor, and a fully automated pipeline combining imaging metrics with clinical variables outperformed the International Prognostic Index, the field’s long-standing standard, for progression-free and overall survival prediction. In a striking analysis of 1,268 patients from the phase III GOYA trial, the automated tool even flagged a high-risk subgroup for central nervous system relapse, a rare but devastating metastatic pattern that baseline imaging had not previously been leveraged to anticipate.
Because supervised deep learning normally demands enormous annotated datasets, researchers have also turned to cleverer training strategies. Semi-supervised approaches that blend classical fuzzy clustering loss functions with U-Net training matched or beat fully supervised baselines using limited labels. Transfer learning frameworks trained on limited annotations generalized across six different cancer types, including lymphoma, and generative adversarial networks that synthesize metabolically enhanced images boosted the performance of independent segmentation models. Even the scans themselves are being compressed: a self-attention U2Net framework cut PET acquisition time by 50 percent while preserving diagnostic quality, and a deep neural network classified FDG PET/CT scans with and without hypermetabolic tumor sites with an area under the curve of 0.95 in a dual-center retrospective analysis.
The second frontier is differential diagnosis, where machine learning models are moving PET/CT from a staging tool toward a non-invasive diagnostic instrument. One of the most clinically consequential applications is predicting bone marrow involvement, which currently requires invasive biopsy and is vulnerable to sampling error. An interpretable multicenter model combining clinical data, PET parameters, radiomic features, and deep learning features achieved an area under the curve of 0.886, with explainability analysis identifying PET radiomic signatures, platelet count, and B symptoms as the dominant predictors. Such tools could spare many patients an unnecessary bone marrow procedure while catching cases that biopsy misses.
Subtype classification follows a similar logic. Because aggressive and indolent lymphomas demand fundamentally different treatment strategies, and because a single needle biopsy may not capture spatially heterogeneous disease, imaging-based classifiers offer a complementary window. A pseudo spatial-temporal radiomics approach exploits intratumoral metabolic heterogeneity by simulating recurrent network behavior across multi-threshold tumor volumes, outperforming conventional radiomics in tumor classification. An ensemble model built on super-resolution imaging predicted lymphoma type with 94.8 percent accuracy, while a hybrid few-shot multiple-instance learning framework distinguished aggressive diffuse large B-cell lymphoma from indolent follicular lymphoma with an area under the curve of 0.795 despite limited annotated training data. Beyond lymphoma itself, deep convolutional networks separated sarcoidosis from lymphoma on maximum-intensity-projection PET images with an area under the curve of 0.963, radiomics-guided machine learning matched or exceeded physician performance in the same discrimination task across more than 400 patients, and computer-aided models distinguished cervical lymph node metastasis from lymphoma involvement with an area under the curve of 0.901. Machine learning models have even begun separating mass-forming pancreatic lymphoma from pancreatic carcinoma, one of the trickiest diagnostic mimics in oncology imaging.
Prognostic stratification, however, is where the authors see the deepest transformation. Conventional tools, including the International Prognostic Index, the NCCN-IPI, and the five-point Deauville score, capture only crude dimensions of tumor biology. AI models now extract high-throughput textural features, spatial dissemination patterns, and deep image signatures that quantify heterogeneity the human eye cannot grade. In diffuse large B-cell lymphoma, multi-timepoint radiomics models combining baseline and end-of-treatment scans beat traditional indices at predicting two-year progression, and deep learning scores extracted from standard network architectures demonstrated robust stability in multicenter external validation. The field is also fusing modalities: one prognostic index merged deep learning PET biomarkers with genetic subtypes to offer regimen-specific risk discrimination, and automated machine learning pipelines built multimodal PET/CT deep feature signatures for survival prediction in elderly patients. Graph neural networks, which convert PET scans into attributed lesion graphs fused with clinical data through cross-attention mechanisms, are emerging as a leading answer to the black-box problem, identifying which specific lesions drive high-risk predictions while maintaining accuracy.
The review is candid that progress is uneven across subtypes and settings. In Hodgkin lymphoma, machine learning models predicted two-year event-free survival with an area under the curve of 0.81, and a low-cost algorithm combining routine blood tests offers interim response assessment for children in regions without PET scanner access. In extranodal NK/T-cell lymphoma, a deep learning system integrating segmentation, image fusion, and prognosis yielded reliable survival predictions in multicenter cohorts, while weakly supervised approaches compensated for missing follow-up data. Yet a sobering counterexample from a prospective trial with PET-guided consolidation strategies found that radiomic features added no significant predictive gain, a reminder that the value of any AI model depends on the clinical context and existing interventions around it.
The path to routine clinical use now runs through validation, standardization, and trust. Only four of the 53 reviewed studies were prospective, and just 20 included independent external validation, leaving most models exposed to selection bias and local protocol overfitting. The authors call for standardized imaging protocols, federated learning to navigate privacy regulations, seamless integration with hospital information and picture archiving systems, rigorous regulatory pathways appropriate for Class III medical devices, and explainable AI architectures that map imaging features onto biological mechanisms. If those conditions are met, the trajectory is clear: PET/CT-based AI is evolving from a manual feature-extraction exercise into automated, interpretable, multimodal decision support that, combined with genomics and longitudinal clinical data, could finally deliver the personalized, precision management that lymphoma’s extraordinary heterogeneity has always demanded.
Subject of Research: Artificial intelligence-based analysis of FDG PET/CT imaging for automated lesion segmentation, differential diagnosis, and prognostic stratification in lymphoma
Article Title: Artificial intelligence-based PET/CT analysis in lymphoma: segmentation, differential diagnosis, and prognostic stratification
Article References: Liu, Q., Sun, R., Chen, X., & Liu, Y. (2026). Artificial intelligence-based PET/CT analysis in lymphoma: segmentation, differential diagnosis, and prognostic stratification. Holistic Integrative Oncology, 5(1), Article 73. https://doi.org/10.1007/s44178-026-00294-5
Image Credits: AI Generated
DOI: 10.1007/s44178-026-00294-5
Keywords: lymphoma, PET/CT, artificial intelligence, deep learning, radiomics, tumor segmentation, total metabolic tumor volume, prognostic stratification, differential diagnosis, convolutional neural networks, graph neural networks, precision medicine
Cite Scienmag News
APA MLA Chicago
Nathaniel Bowman. (September 21, 2026). AI Turns Lymphoma PET/CT Scans Into Automated Diagnosis and Survival Forecasts. Scienmag. https://scienmag.com/ai-turns-lymphoma-pet-ct-scans-into-automated-diagnosis-and-survival-forecasts/
Nathaniel Bowman. “AI Turns Lymphoma PET/CT Scans Into Automated Diagnosis and Survival Forecasts.” Scienmag, 21 September 2026, https://scienmag.com/ai-turns-lymphoma-pet-ct-scans-into-automated-diagnosis-and-survival-forecasts/. Accessed 21 September 2026.
Nathaniel Bowman. “AI Turns Lymphoma PET/CT Scans Into Automated Diagnosis and Survival Forecasts.” Scienmag. September 21, 2026. https://scienmag.com/ai-turns-lymphoma-pet-ct-scans-into-automated-diagnosis-and-survival-forecasts/
Copy citation Download RIS
Tags: Artificial Intelligenceconvolutional neural networksdeep learningdifferential diagnosisGraph Neural NetworkslymphomaPET/CTPrecision medicineprognostic stratificationradiomicstotal metabolic tumor volumetumor segmentation
